204 papers
Cancer biology explores the complex ways cells grow out of control, investigating the genetic mutations and environmental factors that drive tumor formation. This field seeks to understand how healthy cells transform into malignant ones and how these rogue cells spread throughout the body. By decoding these fundamental mechanisms, researchers aim to develop more effective treatments that target the disease at its source while sparing healthy tissue.
At Gist.Science, we process every new preprint published in this category directly from bioRxiv to ensure you stay ahead of the curve. Our team provides both accessible plain-language overviews and detailed technical summaries for each study, bridging the gap between raw research data and practical understanding. Whether you are a specialist or a curious reader, our goal is to make these critical findings clear and actionable.
Below are the latest papers in cancer biology, offering fresh insights into the ongoing fight against this disease.
This study demonstrates that Sox10 is essential for tumor initiation, cancer stem cell activity, and metastasis in HER2+ mammary cancers, as its genetic ablation prevents tumor formation and reprograms luminal tumor cells into a basal phenotype.
This study reveals that cancer cells adapting to drug stress undergo a non-random, selection-independent process of mega-frequency mutagenesis during pseudo-senescence, generating tens of thousands of precise, recurrent mutations at specific transcription factor binding sites that drive drug resistance.
This study reveals that in aggressive acute myeloid leukemia, eIF4E and Ezrin physically interact within pseudopods to establish a localized translation program (T-PODs) that drives cell motility and disease progression, a mechanism validated using the novel VISTA-R technique for visualizing active ribosomes in situ.
This study characterizes the diverse landscape of KIT mutations in Asian melanoma and demonstrates that specific variants exhibit distinct drug sensitivities, thereby establishing a critical evidence base to replace the current "one-size-fits-all" treatment approach with genotype-guided precision medicine strategies.
This study reveals that physiologic hypoxia in lung cancer induces translational arrest and sequestration of MHC class I antigen processing pathway mRNAs into stress granules, thereby blocking immunopeptide presentation and establishing a state of "immunogenic dormancy" that facilitates immune escape.
This study integrates network biology and machine learning to identify Aminoadipate Semialdehyde Synthase (AASS) as a novel prognostic metabolic tumor suppressor biomarker in triple-negative breast cancer.
This study identifies nine cases where LINE-1 retrotransposition insertions cause MET exon 14 skipping in cancer, establishing this mechanism as a recurrent and clinically actionable driver of oncogenic signaling.
Using super-resolution microscopy, this study reveals that estrogen receptor activity dynamically regulates the structural conformation of H3K27ac-marked chromatin, transitioning between open, active states and compact, inactive states, thereby challenging the notion that this epigenetic mark alone is sufficient for enhancer activation and offering new insights into endocrine therapy resistance in breast cancer.
This study establishes a biopsy-compatible ex vivo drug sensitivity testing platform for rare solid tumors that successfully identifies actionable drug responses and demonstrates a significant correlation between high in vitro sensitivity and improved clinical outcomes, supporting its use as a complementary tool in precision oncology.
This study employs an integrative systems-level transcriptomic analysis to reveal that gastric cancer progression is driven by coordinated chromatin-level developmental reprogramming, characterized by the upregulation of HOX genes and loss of gastric differentiation markers, alongside FGFR-mediated oncogenic signaling and stage-dependent metabolic disruption.